Clinical Trial Update: Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating escalating doses of PM01183 in combination with fixed doxorubicin in advanced unresectable solid tumors; study completed with results p…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrial Adenocarcinomas
• Neuroendocrine Tumors
• Small Cell Lung Cancer

Drugs mentioned

• Doxorubicin (doxorubicin)
• PM01183 (PM01183)

Snippet

Sponsor: PharmaMar | Conditions: Endometrial Adenocarcinomas, Neuroendocrine Tumors | Phase 1 | Status: COMPLETED | Results posted: 2020-03-09